Neuroblastoma 2

Common Name(s)

Neuroblastoma 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 2" returned 158 free, full-text research articles on human participants. First 3 results:

PHOX2A and PHOX2B are differentially regulated during retinoic acid-driven differentiation of SK-N-BE(2)C neuroblastoma cell line.
 

Author(s): Simona Di Lascio, Elena Saba, Debora Belperio, Andrea Raimondi, Helen Lucchetti, Diego Fornasari, Roberta Benfante

Journal: Exp. Cell Res.. 2016 Mar;342(1):62-71.

 

PHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma (NB), because of their over-expression in different NB cell lines and tumour samples. We ...

Last Updated: 18 Mar 2016

Go To URL
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
 

Author(s): Rachel Tanos, Dipan Karmali, Srilatha Nalluri, Kelly C Goldsmith

Journal:

 

Pediatric patients with high-risk neuroblastoma (HR NB) often fail to respond to upfront intensive multimodal therapy. Tumor-acquired suppression of apoptosis contributes to therapy resistance. Many HR NB tumors depend on the anti-apoptotic protein Bcl-2 for survival, through Bcl-2 ...

Last Updated: 15 Feb 2016

Go To URL
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
 

Author(s): Nikolai Siebert, Christin Eger, Diana Seidel, Madlen Jüttner, Maxi Zumpe, Danilo Wegner, Silke Kietz, Karoline Ehlert, Gareth J Veal, Werner Siegmund, Michael Weiss, Hans Loibner, Ruth Ladenstein, Holger N Lode

Journal: MAbs. 2016 ;8(3):604-16.

 

Ch14.18 manufactured in Chinese hamster ovary (CHO) cells is currently being evaluated in clinical trials. Short-term infusion (STI) (8-20 h/day; 4-5 days) of 100 mg/m2 ch14.18/CHO (dinutiximab β) per cycle in combination with cytokines is standard treatment of neuroblastoma (NB) ...

Last Updated: 25 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 2" returned 1 free, full-text review articles on human participants. First 3 results:

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
 

Author(s): Brett H Yamane, Jacquelyn A Hank, Mark R Albertini, Paul M Sondel

Journal: Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000.

 

Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL2 (EMD-273063) was developed by means of fusion of two molecules of IL-2 to the monoclonal ...

Last Updated: 24 Jun 2009

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma

 

Last Updated: 9 Jan 2017

Go to URL
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; High-Risk

 

Last Updated: 14 Sep 2016

Go to URL
4SCAR-GD2 Targeting Refractory and/or Recurrent Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; Effects of Immunotherapy

 

Last Updated: 4 May 2016

Go to URL